Evidence map›Paper›PMID 32784666›Full record

ArticleMaterials (Basel, Switzerland)2020

Ruthenium(II) and Iridium(III) Complexes as Tested Materials for New Anticancer Agents.

Joanna Masternak, Agnieszka Gilewska, Barbara Barszcz, Iwona Łakomska, Katarzyna Kazimierczuk, Jerzy Sitkowski, Joanna Wietrzyk, Anna Kamecka, Magdalena Milczarek

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Cytotoxic Organometallic Iridium(III) Complexes.Molecules (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Joanna MasternakInstitute of Chemistry, Jan Kochanowski University, Uniwersytecka 7, 25-406 Kielce, Poland.ORCID 0000-0002-8785-3879
Agnieszka GilewskaInstitute of Chemistry, Jan Kochanowski University, Uniwersytecka 7, 25-406 Kielce, Poland.
Barbara BarszczInstitute of Chemistry, Jan Kochanowski University, Uniwersytecka 7, 25-406 Kielce, Poland.
Iwona ŁakomskaFaculty of Chemistry, Nicolaus Copernicus University in Toruń, Gagarina 7, 87-100 Toruń, Poland.ORCID 0000-0002-9666-2134
Katarzyna KazimierczukDepartment of Inorganic Chemistry, Faculty of Chemistry, Gdańsk University of Technology, Narutowicza 11/12 G., 80-233 Gdańsk, Poland.ORCID 0000-0002-0821-376X
Jerzy SitkowskiInstitute of Organic Chemistry, Polish Academic of Science, Kasprzaka 44/52, 01-224 Warszawa, Poland.ORCID 0000-0002-9962-6024
Joanna WietrzykHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wrocław, Poland.ORCID 0000-0003-4980-6606
Anna KameckaInstitute of Chemistry, Faculty of Sciences, University of Natural Sciences and Humanities in Siedlce, 3 Maja 54, 08-110 Siedlce, Poland.
Magdalena MilczarekHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wrocław, Poland.ORCID 0000-0001-6696-5305
Jan Kochanowski University · PLLudwik Hirszfeld Institute of Immunology and Experimental Therapy · PLGdańsk University of Technology · PLInstitute of Organic Chemistry · PLNicolaus Copernicus University · PLUniversity of Siedlce · PL

Funding

Financial support from the statutory activity of subsidy from the Polish Ministry of Science and Higher Education for the Institute of Chemistry of the University of of Jan Kochanowski Financial support from the statutory activity of subsidy from the Polish Ministry of Science and Higher Education for the Institute of Chemistry of the University of of Jan KochanowskiPublication costs were supported by the Nicolaus Copernicus University in Toruń (Excellence Initiative - Research University) Excellence Initiative - Research University
6 · The paper itself

Abstract

The oncological use of cisplatin is hindered by its severe side effects and a very important resistance problem. To overcome these problems, scientists have attempted to design new generation transition-metal anticancer complexes. In this study, we present new complexes, ruthenium(II) [(η

Indexed as

cytotoxicityDNA interactionsiridium(III) complexesruthenium half-sandwich

Identifiers

PMID32784666
PMCPMC7475896
OpenAlexW3047678898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.